Global Alzheimer's Drugs Market Outlook, 2031

The global Alzheimer's drugs industry covers medicines used to treat Alzheimer's disease, the most common cause of dementia, which affects tens of millions of people worldwide and is expected to grow sharply as populations age. For decades treatment relied on symptomatic drugs, including the cholinesterase inhibitors donepezil, rivastigmine and galantamine and the NMDA receptor antagonist memantine, all of which are now widely available as low-cost generics and do not change the course of the disease. The market was transformed by the arrival of anti-amyloid monoclonal antibodies that remove amyloid plaques from the brain and modestly slow cognitive decline in early-stage patients. Eisai and Biogen's Leqembi (lecanemab) received full FDA approval in July 2023, and Eli Lilly's Kisunla (donanemab) was approved in July 2024, following the troubled accelerated approval and eventual discontinuation of Biogen's Aduhelm in 2024. Other companies active in the field include Roche, with its brain-shuttle antibody trontinemab in phase 3, Novo Nordisk, AbbVie, Johnson & Johnson, Novartis, Anavex, Cassava, Acadia, Otsuka and Lundbeck for agitation, and many biotechnology companies targeting tau, neuroinflammation, synaptic function and metabolic pathways. Diagnostic companies such as Roche Diagnostics, Fujirebio, C2N Diagnostics and Quanterix are central to the market because anti-amyloid therapies require confirmation of amyloid pathology before treatment. The approval of anti-amyloid antibodies marked the first time a therapy had been shown in large phase 3 trials to slow the progression of Alzheimer's disease, but uptake has been gradual. Treatment requires amyloid confirmation by PET scan or cerebrospinal fluid test, genetic testing for APOE4 status, regular infusions and MRI monitoring for amyloid-related imaging abnormalities, known as ARIA, which can cause brain swelling or bleeding. Health systems have had to build capacity for diagnosis, infusion and imaging, and reimbursement decisions have varied. In the United States, Medicare began covering the drugs with a patient registry after traditional approval, while the European Union approved Leqembi in April 2025 and Kisunla in September 2025 for patients without two copies of APOE4, and England's NICE decided in 2025 not to recommend either drug for NHS use on cost-effectiveness grounds. Delivery has become easier since 2025, when blood tests such as Fujirebio's Lumipulse plasma assay received FDA clearance to support diagnosis and the FDA approved subcutaneous Leqembi Iqlik for maintenance dosing in August 2025 and for initiation in July 2026, allowing treatment at home from the first dose. Leqembi sales have grown steadily as more specialist centres adopt the therapy. The pipeline has also had setbacks, most notably Novo Nordisk's announcement in November 2025 that oral semaglutide failed to slow disease progression in the EVOKE trials, dampening hopes that GLP-1 drugs could treat Alzheimer's. Market Dynamics Market Drivers • Ageing Populations and Rising Dementia PrevalenceThe number of people living with dementia is expected to rise substantially by 2050 as populations age in Europe, North America, East Asia and increasingly in emerging economies. Alzheimer's disease accounts for the majority of cases and imposes enormous costs on families, health systems and long-term care. Governments and payers therefore place a high value on therapies that delay progression and keep patients independent for longer, supporting investment in both disease-modifying and symptomatic drugs. • Earlier Diagnosis Through Blood BiomarkersBlood tests measuring phosphorylated tau and amyloid ratios, such as Fujirebio's Lumipulse plasma test cleared by the FDA in May 2025 and Roche's Elecsys assays, allow doctors to identify Alzheimer's pathology more cheaply and conveniently than PET scans or lumbar punctures. Easier diagnosis increases the number of patients who can be identified at the early stage when anti-amyloid therapies are indicated, and it enables screening in primary care and recruitment into prevention trials. Market Challenges • Safety Monitoring and Treatment ComplexityAnti-amyloid antibodies can cause ARIA, including brain oedema and microhaemorrhages, which are more common in patients carrying the APOE4 gene and occasionally cause serious harm. Patients need genetic testing, repeated MRI scans and specialist oversight, and those on anticoagulants may face additional risks. These requirements strain neurology, imaging and infusion capacity, and many eligible patients live far from centres able to provide treatment, limiting uptake. • Modest Benefit, High Cost and Reimbursement BarriersClinical trials showed that lecanemab and donanemab slow decline by roughly a quarter to a third over 18 months, a benefit some clinicians and payers consider modest relative to cost and risk. Annual drug prices in the United States exceed USD 25,000 before diagnostic and monitoring costs. Health technology assessment bodies, including NICE in England, have concluded that the drugs are not cost-effective at current prices, restricting access in public health systems. Market Trends • Subcutaneous and Next-Generation Anti-Amyloid TherapiesDevelopers are making anti-amyloid treatment easier to deliver and potentially safer. Leqembi Iqlik allows weekly subcutaneous injection at home for both initiation and maintenance, and Kisunla's fixed-duration dosing lets patients stop once plaques are cleared. Roche's trontinemab uses a brain-shuttle design to increase antibody delivery to the brain and has shown rapid plaque clearance with lower ARIA rates in early trials, while other companies are testing oral and vaccine approaches. • Diversification Beyond AmyloidThe pipeline increasingly targets tau, neuroinflammation, microglial function, synaptic protection, vascular factors and metabolic pathways. Anti-tau antibodies and antisense drugs, TREM2 agonists, APOE-targeted therapies and combination regimens are in clinical development. Trials are also moving earlier, into people with amyloid pathology but no symptoms, to test whether prevention is possible. Treatments for Alzheimer's-related agitation and psychosis, such as Rexulti, form another growing area. Segment Analysis Cholinesterase inhibitors, including donepezil, rivastigmine and galantamine, are the most widely prescribed Alzheimer's drugs and are used across mild, moderate and severe stages to modestly improve memory and function. They are available as low-cost generics in tablets, oral solutions and, for rivastigmine, transdermal patches. Memantine, an NMDA receptor antagonist, is used in moderate to severe disease, often combined with donepezil in a fixed-dose capsule. Together these drugs treat millions of patients but generate relatively little revenue because of generic competition. Anti-amyloid monoclonal antibodies, Leqembi and Kisunla, are the first disease-modifying therapies for early Alzheimer's and account for the fastest-growing share of market value. They are given by intravenous infusion, and Leqembi is also available as a subcutaneous autoinjector. Drugs for behavioural and psychological symptoms, including brexpiprazole approved in the United States for agitation associated with Alzheimer's dementia in 2023, antidepressants and sleep medications, form an additional segment. Pipeline products include anti-tau antibodies, brain-shuttle antibodies, oral small molecules targeting amyloid aggregation, sigma-1 receptor agonists such as blarcamesine, anti-inflammatory drugs and vaccines. Traditional Chinese medicines and approved drugs in specific countries, such as China's GV-971, add regional segments. Mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's dementia together form the early symptomatic stage, which is the only population in which Leqembi and Kisunla are approved. Identifying these patients requires memory clinics, cognitive testing and biomarker confirmation, and blood tests are making identification easier. Moderate Alzheimer's disease is treated with cholinesterase inhibitors and memantine, alongside management of behavioural symptoms, and patients at this stage often need increasing care. Severe Alzheimer's disease is managed mainly with memantine, donepezil at higher doses, and supportive and palliative care, often in nursing homes. Preclinical Alzheimer's disease, in which amyloid is present but symptoms have not yet appeared, is not yet a treated population, but large prevention trials, such as the AHEAD 3-45 study of lecanemab and TRAILBLAZER-ALZ 3 of donanemab, aim to open this segment. Early-onset and genetically defined forms, including autosomal dominant Alzheimer's disease and Down syndrome-associated Alzheimer's disease, are studied in dedicated trials. Mixed dementia, where Alzheimer's pathology coexists with vascular disease or Lewy bodies, complicates treatment decisions. The shift toward early-stage treatment is changing where patients are managed, moving diagnosis into primary care and specialist memory services. Oral tablets and capsules, including generic donepezil, galantamine and memantine, are the standard route for symptomatic treatment, and orally disintegrating tablets and oral solutions help patients who have difficulty swallowing. Transdermal patches, such as rivastigmine and donepezil patches, provide steady drug levels and reduce gastrointestinal side effects, and they are convenient for caregivers. Intravenous infusions are required for Kisunla every four weeks and for Leqembi every two weeks during initiation or every four weeks for maintenance, requiring infusion centres, nursing staff and monitoring. Subcutaneous injection, introduced with Leqembi Iqlik, allows weekly at-home dosing with an autoinjector and could significantly expand treatment capacity by reducing reliance on infusion chairs. Intranasal and intrathecal routes are being studied for some pipeline products, including antisense oligonucleotides against tau that are delivered into the spinal fluid. Long-acting formulations and brain-shuttle antibodies aim to reduce dosing frequency. The choice of route affects treatment settings, costs and patient convenience, and the move from intravenous to subcutaneous delivery is likely to be one of the most important changes over the forecast period. Hospital pharmacies and specialist neurology and memory clinics administer anti-amyloid antibodies, coordinate PET scans, MRI monitoring and genetic testing, and manage ARIA risk, making them the core channel for disease-modifying therapy. In the United States, infusion centres and specialist practices registered in Medicare's data collection registry deliver most treatments. Retail pharmacies dispense the majority of symptomatic drugs, including generic donepezil and memantine, and they are the main channel by prescription volume. Online and mail-order pharmacies are growing, particularly for repeat prescriptions of chronic medications to older patients. Specialty pharmacies will play a larger role as subcutaneous Leqembi Iqlik is dispensed for home use. Long-term care facilities and nursing homes use institutional pharmacies to supply medications for patients with moderate to severe disease. Diagnostic laboratories and imaging centres are closely linked to the treatment channel because they determine eligibility. Government programmes, such as Medicare in the United States and national health services in Europe and Japan, influence which channels are used through reimbursement rules. Regional Analysis North America, led by the United States, is the largest market for Alzheimer's drugs. The FDA approved Leqembi in 2023 and Kisunla in 2024, Medicare covers the therapies with registry participation, and the country has extensive PET imaging, MRI and neurology capacity, although access remains uneven. Blood tests cleared by the FDA in 2025 and subcutaneous Leqembi approvals in 2025 and 2026 are expected to broaden adoption. The United States is also home to Eli Lilly, Biogen and many biotechnology companies developing new therapies. Canada approved Leqembi more slowly. Asia-Pacific has the largest number of people with dementia, and Japan approved Leqembi in 2023 with national health insurance coverage, becoming one of its largest markets, while China approved Leqembi in 2024 and has a large self-pay market in major cities. South Korea, Taiwan and other Asian markets have also approved anti-amyloid therapies, while Australia's regulator approved donanemab in 2025 after declining to register lecanemab. Europe approved Leqembi in April 2025 and Kisunla in September 2025 for patients who are not APOE4 homozygotes, but reimbursement varies by country, and NICE in England did not recommend either drug. Latin America, the Middle East and Africa rely mainly on generic symptomatic drugs, with limited access to biomarker testing and disease-modifying therapies, though private hospitals in Brazil, Mexico and the Gulf states have begun to offer them. Key Developments July 2026: The FDA approved once-weekly subcutaneous Leqembi Iqlik for starting treatment in early Alzheimer's disease, making it the first anti-amyloid therapy that can be given subcutaneously throughout treatment. November 2025: Novo Nordisk reported that oral semaglutide did not slow disease progression in its phase 3 EVOKE and EVOKE+ trials in early Alzheimer's disease. September 2025: Donanemab was approved in the EU for early Alzheimer's disease in adults who are not APOE4 homozygotes, following Leqembi's EU approval in April 2025. August 2025: The FDA approved a subcutaneous autoinjector formulation of lecanemab for weekly maintenance dosing after 18 months of intravenous treatment. May 2025: The FDA cleared Fujirebio's Lumipulse plasma pTau217/beta-amyloid 1-42 ratio test to help identify amyloid pathology in adults with cognitive symptoms. July 2024: Eli Lilly's donanemab received FDA approval for early symptomatic Alzheimer's disease, with a dosing regimen that allows treatment to stop once amyloid plaques are cleared. Considered in this report • Historic Year: 2020 • Base Year: 2025 • Estimated Year: 2026 • Forecast Year: 2031 Aspects covered in this report • Global Alzheimer's Drugs Market with its value and forecast along with its segments • Various drivers and challenges • Ongoing trends and developments • Top profiled companies • Strategic recommendation By Drug Class • Cholinesterase Inhibitors • NMDA Receptor Antagonists • Anti-Amyloid Monoclonal Antibodies • Drugs for Behavioural Symptoms • Pipeline Therapies By Disease Stage • Mild Cognitive Impairment • Mild Alzheimer's Disease • Moderate Alzheimer's Disease • Severe Alzheimer's Disease By Route of Administration • Oral • Transdermal • Intravenous • Subcutaneous By Distribution Channel • Hospital Pharmacies and Memory Clinics • Retail Pharmacies • Online Pharmacies • Specialty Pharmacies • Long-Term Care Pharmacies

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Sikandar Kesari

Research Analyst

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now